Correction to: Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management

Correction to: Journal of Neurology https://doi.org/10.1007/s00415-023-11910-z.

In the original version of this article, mistakes were noticed in Table 1 and Table 2.

In the Table 1, text in the column “Application” and row “Ravulizumab” which previously read:

i. v., weight-based², loading dose of 2400–3000 mg on days 1 and 15 followed by 3000–3600 mg once every 8 weeks.

Should have read:

i. v., weight-based², loading dose of 2400–3000 mg on day 1 followed by the maintenance dose (3000–3600 mg) after 2 weeks and then once every 8 weeks.

In the Table 2, text in the column “Inclusion criteria” and row “Ravulizumab” which previously read:

 ≥ 2 attacks in 12 months or ≥ 3 attacks in 24 months with 1 attack in the last 12 months.

Should have read:

 ≥ 1 relapse in the last 12 months.

The corrected Tables 1 and 2 are given in the following page:

Table 1 Recommendations on the application, monitoring, and important risks of preventive immunotherapies in NMOSD^1,2

Table 2 Main data of randomized, double-blind, placebo-controlled, time-to-event trials in NMOSD